UA99259C2 - Treating obesity with muscarinic receptor m1 antagonists - Google Patents
Treating obesity with muscarinic receptor m1 antagonistsInfo
- Publication number
- UA99259C2 UA99259C2 UAA200900269A UAA200900269A UA99259C2 UA 99259 C2 UA99259 C2 UA 99259C2 UA A200900269 A UAA200900269 A UA A200900269A UA A200900269 A UAA200900269 A UA A200900269A UA 99259 C2 UA99259 C2 UA 99259C2
- Authority
- UA
- Ukraine
- Prior art keywords
- mantagonist
- acetylcholine receptor
- muscarinic acetylcholine
- treating obesity
- antagonists
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Provided are methods of treating obesity and effecting desired weight loss or preventing undesired weight gain by administration of a preferential muscarinic acetylcholine receptor Mantagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor Mantagonist. The preferential muscarinic acetylcholine receptor Mantagonist, optionally can be administered with an anti-obesity agent, for example, an anorexiant. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor Mantagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor Mantagonist.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80506606P | 2006-06-16 | 2006-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA99259C2 true UA99259C2 (en) | 2012-08-10 |
Family
ID=40829458
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200900269A UA99259C2 (en) | 2006-06-16 | 2007-06-15 | Treating obesity with muscarinic receptor m1 antagonists |
UAA200900268A UA98938C2 (en) | 2006-06-16 | 2007-06-15 | Treating psychological conditions using muscarinic receptor m1 antagonists |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200900268A UA98938C2 (en) | 2006-06-16 | 2007-06-15 | Treating psychological conditions using muscarinic receptor m1 antagonists |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN101472476B (en) |
UA (2) | UA99259C2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8748419B2 (en) | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
DK2632468T3 (en) * | 2010-10-25 | 2018-02-12 | Univ Manitoba | THERAPEUTIC COMPOSITIONS FOR SYMMETRIC DIABETIC POLYNEuropathy |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3953430A (en) * | 1975-02-24 | 1976-04-27 | American Cyanamid Company | Substituted benzodiazepin-10-ones and method of use |
US5668155A (en) * | 1988-05-10 | 1997-09-16 | The General Hospital Corporation | Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders |
US6803357B1 (en) * | 1998-02-02 | 2004-10-12 | New England Medical Center Hospitals, Inc. | Method of regulating glucose metabolism, and reagents related thereto |
WO2002022579A2 (en) * | 2000-09-11 | 2002-03-21 | Sepracor, Inc. | Antipsychotic sulfonamide-heterocycles, and methods of use thereof |
EP1369129A4 (en) * | 2001-03-14 | 2005-08-03 | Ono Pharmaceutical Co | Remedies for depression containing ep1 antagonist as the active ingredient |
US20040204472A1 (en) * | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
BRPI0506807A (en) * | 2004-04-22 | 2007-05-29 | Mor Research Applic Ltd | food consumption management method and pharmacological composition |
-
2007
- 2007-06-15 CN CN200780022570.9A patent/CN101472476B/en not_active Expired - Fee Related
- 2007-06-15 CN CN2007800224176A patent/CN101472571B/en not_active Expired - Fee Related
- 2007-06-15 UA UAA200900269A patent/UA99259C2/en unknown
- 2007-06-15 UA UAA200900268A patent/UA98938C2/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101472571A (en) | 2009-07-01 |
CN101472476A (en) | 2009-07-01 |
CN101472476B (en) | 2013-10-30 |
UA98938C2 (en) | 2012-07-10 |
CN101472571B (en) | 2012-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009050136A3 (en) | Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome | |
EP2056818A4 (en) | Compositions and methods for neuroprotection | |
MX2010002781A (en) | Novel combination of therapeutic agents. | |
WO2008024485A3 (en) | Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent | |
EP2032127A4 (en) | Treating psychological conditions using muscarinic receptor m1 antagonists | |
WO2007098113A3 (en) | Ccr3 inhibition for ocular angiogenesis and macular degeneration | |
WO2006015259A3 (en) | Compounds and compositions as modulators of steroid hormone nuclear receptors | |
WO2012037411A3 (en) | Estrogen receptor modulators and uses thereof | |
UA94909C2 (en) | Pharmaceutical composition of a neuroactive steroid and use thereof | |
WO2007121483A3 (en) | Pre-mixed, ready-to-use iv bolus compositions and methods of use | |
BRPI0510170B8 (en) | compound, pharmaceutical composition for the treatment of diseases mediated by the muscarinic acetylcholine receptor and use of the compound | |
WO2006055752A3 (en) | INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHODS OF USING THE SAME | |
WO2006036770A3 (en) | Combination therapy for the treatment of obesity | |
WO2004110368A3 (en) | Combination therapy for the treatment of hypertension | |
WO2006135638A3 (en) | Tanaproget compositions containing ethinyl estradiol | |
WO2006058059A3 (en) | Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject | |
WO2009140642A3 (en) | Tricyclic antagonists of prostaglandin d2 receptors | |
WO2006065722A3 (en) | Compositions and methods for pulmonary conditions | |
WO2007051062A3 (en) | Substituted dihydropyridines and methods of use | |
WO2005077968A3 (en) | 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity | |
WO2005112633A3 (en) | Compounds and compositions for delivering active agents | |
WO2007048026A3 (en) | Cgrp peptide antagonists and conjugates | |
NZ588913A (en) | Liver cancer drug | |
MY184864A (en) | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist | |
CL2007003266A1 (en) | COMPOUNDS DERIVED FROM PROGESTERONA, ANTAGONISTS OF THE PROGESTERONE RECEIVER; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF ENDOMETRIOSIS, MYOMAS OR TUMORS DEPENDENT ON HORMONES. |